Sign in
Active, not recruitingNo phase

Prostate Cancer Screening With Abbreviated MRI Protocol

Key facts

Who runs it
Masaryk Memorial Cancer Institute
Where
Czechia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
300 people, planned
Started
1 May 2022
Expected to end
31 Dec 2026
Type of study
Interventional
Treatments tested
  • magnetic resonance
  • serum PSA examination
  • Biopsy
Record updated
10 November 2026

Who can take part

Age
50 years to 69 years
Sex
Men only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Age 50-69 years
  • Life expectancy over 10 years
  • Ability to undergo all planned procedures (without contraindications to MRI or biopsy)
  • No known prostate cancer or prostate biopsy in the past (interventions for BPH are not a restriction)
  • No PSA test or prostate MRI in the past 2 years
  • No signs of prostatitis or urinary tract infection in the past 6 months
  • Signed informed consent

Who cannot take part

  • Contraindications to MRI
  • Hip replacement
  • Known BRCA1/BRCA2 mutation

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Prostate cancer is one of the most common malignancies in the male population with incidence and mortality rates comparable to breast cancer in women, but in contrast, a population screening program that would fulfill all the recommended criteria is not yet available. According to international recommendations, the preventive PSA sampling used in clinical practice is not suitable because of the concurrent detection of clinically insignificant carcinomas in a major proportion of tests. These clinically non-significant cancers make up a significant and increasing proportion with age. Detection of non-significant cancers burdens the health care system and patients with the care that has no positive impact on their health. Current preventive serum prostate-specific antigen (PSA) testing does not distinguish benign hyperplasia and nonsignificant carcinoma from clinically significant cancer. It is therefore not suitable for full-scale screening.

Read full original descriptionShow less

According to current guidelines, magnetic resonance imaging (MRI) is indicated only in patients with an increased risk of cancer for detection or staging after biopsy and is not used for screening. According to recent studies, MRI has detected an increased proportion of significant cancers in the general population compared to screening based on PSA, while fewer clinically insignificant cancers have been detected. In screening, a shorter examination protocol without contrast medium (biparametric MRI) is used with a lower cost per examination, allowing to increase both the number of patients examined and patient comfort.

The main objective of the project is to assess the contribution of imaging in the screening of clinically significant prostate cancer and to validate the published results in the Czech population, and extend the screening model by the second round of examinations and additional laboratory markers. The secondary aim is to design a subsequent study with a larger number of participants allowing statistical evaluation, similar to the successful breast cancer screening.

The group in the trial

  • Preventive prostate examination by bpMRITreatment being tested

    The cohort consists of patients: * with age 50-69 years * without any contraindications to MRI or biopsy * without known status of prostate cancer or prostate biopsy in the past (interventions for BPH are not a restriction) * without known BRCA mutation * without PSA test or prostate MRI in the past 2 years * without any signs of prostatitis or urinary tract infection in the past 6 months.

    Treatment: magnetic resonance, serum PSA examination, and Biopsy

Results explained

A paper that names this trial, explained in plain words.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
ProstaPilot: Prostate Cancer Screening Using MRI With an Abbreviated Protocol
Publications
Record updated
10 November 2026